• 35 Citations
  • 2 h-Index
20132019
If you made any changes in Pure these will be visible here soon.

Personal profile

Education/Academic qualification

PGCert THE, University of Dundee

Doctor of Medicine, University of Cambridge

Bachelor of Arts, University of Cambridge

1 Oct 200630 Jun 2009

External positions

Medical Oncology Registrar, NHS Tayside

10 Sep 2018 → …

Fingerprint Dive into the research topics where Mark Baxter is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 0 Similar Profiles
eribulin Medicine & Life Sciences
Hepatocellular Carcinoma Medicine & Life Sciences
Trifluridine Medicine & Life Sciences
Addison Disease Medicine & Life Sciences
Knee Replacement Arthroplasties Medicine & Life Sciences
Idiopathic Pulmonary Fibrosis Medicine & Life Sciences
Seminoma Medicine & Life Sciences
Airway Resistance Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Projects 2019 2019

Research Output 2013 2019

  • 35 Citations
  • 2 h-Index
  • 9 Article
  • 1 Meeting abstract
  • 1 Conference article
  • 1 Review article
22 Downloads (Pure)

Hypophysitis induced by immune checkpoint inhibitors in a Scottish melanoma population: Immune checkpoint inhibitor toxicity

Wei, K. Z., Baxter, M. & Casasola, R., 18 Apr 2019, In : Melanoma Management. 6, 1, 12 p., MMT13.

Research output: Contribution to journalArticle

Open Access
File
Melanoma
Population
Hypophysitis
Disease-Free Survival
Demography

Metastatic seminoma with isolated gastric metastases: a case report

Mclaren, A., Baxter, M. A., Katbeh, T., Lynch, V., Fullarton, G. & White, J., 25 Jun 2019, In : Scottish Medical Journal. 5 p.

Research output: Contribution to journalArticle

Open Access
File
Seminoma
Stomach
Neoplasm Metastasis
Orchiectomy
Groin
1 Citation (Scopus)

Real-world experience of trifluridine/tipiracil in patients with metastatic colorectal cancer: A multicenter United Kingdom study

Stavraka, C., Pouptsis, A., Kabuubi, P., Angelis, V., Baxter, M., Barrie, A., Costa, A., Nizam, A., De Naurois, J., Mikropoulos, C., Hill, M., Graham, J., Harris, V., Bridgewater, J. & Ross, P., 1 Feb 2019, In : Journal of Clinical Oncology. 37, 4, p. 668-668 1 p.

Research output: Contribution to journalMeeting abstract

Trifluridine
Colorectal Neoplasms
irinotecan
oxaliplatin
Thymidine Phosphorylase

Eribulin in metastatic breast cancer the UK experience,- a multi-centre retrospective 577 patient study

Jafri, M., Kristeleit, H., Misra, V., Baxter, M., Ahmed, S., Jegnnathen, A., Jain, A., Maskell, D., Barthakur, U., Edwards, G., Walter, H., Walter, R., Khan, M. A., Borley, A., Nightingale, P. & Rea, D., Oct 2018, In : Annals of Oncology. 29, Supplement 8, 1 p., 313P.

Research output: Contribution to journalConference article

eribulin
Breast Neoplasms
Survival
1 Citation (Scopus)
39 Downloads (Pure)

Lenvatinib and its use in the treatment of unresectable hepatocellular carcinoma

Baxter, M. A., Glen, H. & Evans, T. R. J., Aug 2018, In : Future Oncology. 14, 20, p. 2021-2029 9 p.

Research output: Contribution to journalArticle

Open Access
File
Hepatocellular Carcinoma
Therapeutics
Protein-Tyrosine Kinases
Survival
lenvatinib